Greenrise Global’s medical cannabis subsidiary announces the introduction of its product Dronabinol to the German market

BERLIN and ERFURT, Germany, November 17, 2021 / CNW / – Greenrise Global Brands Inc. (formerly AMP Alternative Medical Products Inc.) (Frankfurt: C4T) (ISIN: CA39540L1085) (CSE: XCX), a wholly owned subsidiary of AMP Alternative Medical Products GmbH (“AMP”) , a pharmaceutical supplier of medical cannabis products to German pharmacies, announces the launch of a new dronabinol-based medical cannabis product available in pharmacies from January 2022.

Greenrise Global Logo (CNW Group / Greenrise Global Brands Inc.)

Dronabinol is pure tetrahydrocannabinol (THC) and is registered as an active pharmaceutical ingredient (API).

AMP’s dronabinol product is’ Made in Germany. “It will be competitively priced and complements AMP’s product portfolio supporting any therapy requiring medicinal cannabis products for the growing range of therapeutic approaches prescribed by a growing number of physicians.

Dronabinol is a leading medical cannabis product in Germany for many years, and it is frequently prescribed by physicians for pain management. Compared to the procedure of preparing vaporized forms of medicinal cannabis, many patients find prescriptions for dronabinol easier to ingest. Doctors believe that the THC concentration in dronabinol is more precise than that of flowers or extracts, which makes it easier to control the dosage. Pharmacists use Dronabinol to fill prescriptions for medications prescribed by doctors for patients, usually in the form of drops or solutions.

Dronabinol is germany most commonly prescribed medical cannabis product, accounting for 35% of all medical cannabis prescriptions and € 46.5 million in sales in 2020. As of Germany, total sales of reimbursed prescription medical cannabis totaled 165 million euros, representing almost 90% of the medical cannabis market in 2020.

The national AMP sales team is currently receiving training with healthcare professionals on the benefits of dronabinol for physician patients and prescription preparation methods for pharmacists.

AMP has selected a German partner as the supplier of dronabinol. Doctors and pharmacists can find more information about the product or order on the AMP website: https://amp-eu.com/doccheck-login

“We expect strong sales of this new product as dronabinol is well known to doctors and insurance companies who often reimburse prescriptions for dronabinol,” said Dr. Stefan Feuerstein, Managing Director of AMP and Chairman and Managing Director of Greenrise Global. AMP’s dronabinol product offers the best quality for patients and the best value for pharmacists and insurance companies compared to the limited number of other products currently on the market. “

About Greenrise Global Brands Inc.

Greenrise Global helps people realize the beneficial properties of cannabis. Greenrise Global is a publicly traded Canadian company with two German operating subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness company based in Hamburg, with brands such as Herbify and CANAVEX® in his wallet. AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including the medical cannabis brands of Aphria, Bedrocan, Little Green Pharma and the AMP branded product line and sold through its national sales team. The AMP complies with the German Narcotics Act (BtMG) and the regulatory requirements of the Free State of Thuringia, ensuring that products imported from all over the world and sold in Germany meet the European Union Good Manufacturing Practices (EU-GMP) standard.

For more information on Greenrise Global, please visit www.greenriseglobal.com

Neither CSE nor its regulatory services provider (as that term is defined in CSE policies) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and timing. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company does not undertake to update them publicly to reflect new information or the occurrence of future events or circumstances, unless the law does not require otherwise.

SOURCE Greenrise Global Brands Inc.

Cision

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/17/c2637.html


Source link

Comments are closed.